Nicolaas Bohnen, MD
Radiology
24 Frank Lloyd Wright Dr., Lobby B, Rm 100
Ann Arbor, Michigan 48105
Manage Your Profile
About
Dr. Bohnen is professor of Radiology and Neurology at the University of Michigan. He attended medical school in the Netherlands and completed a PhD in neuropsychology. He completed residency training in neurology (Mayo Clinic, Rochester, MN) and nuclear medicine (University of Michigan, Ann Arbor, MI). He was a fellow in movement disorders at the University of Michigan Medical Center. He holds clinical appointments in the Departments of Radiology (Division of Nuclear Medicine), Neurology at the University of Michigan, and the Ann Arbor VA (movement and cognitive disorders clinic). Dr. Bohnen’s research interests include the use of PET and MRI in the study of neurodegenerative disorders and normal aging. He is the director of the UM Functional Neuroimaging, Cognitive and Mobility Laboratory where his clinical research has a focus on neurobiological correlates of cognition, vestibular and multisensory processing during gait and postural control, olfaction and mobility in normal aging and in Parkinson disease.
Links
Functional Neuroimaging, Cognitive and Mobility Laboratory (FNICOMO Lab)
Qualifications
-
ResidencyUniversity of Michigan Health, Nuclear Medicine, United States
1996 - 1998
Residency
-
ResidencyMayo Clinic, Neurology, United States
1992 - 1996
Residency
-
EpidemiologyMayo Clinic, Rochester, United States
1991 - 1992
Postdoctoral Fellowship
-
PhDUniversity of Limburg, Maastricht, Maastricht, Netherlands
1987 - 1991
-
MDRabdoud University Nijmegen Medical Centre, Nijmegen, Netherlands
1979 - 1987
Center Memberships
-
Center MemberFrankel Institute for Heart and Brain Health
Research Overview
The Functional Neuroimaging, Cognitive, and Mobility (FNiCoMo) Laboratory is part of the Departments of Radiology and Neurology at the University of Michigan. The mission of this lab is to gain a better understanding of how the architecture of the brain and functional processes in the brain (obtained with functional neuroimaging) determine cognitive functioning and mobility both in patients with neurodegenerative diseases (such as Parkinson's Disease) and in normal aging.
Recent Publications
-
Wu LY, du Toit T, Georgiades T, Stafford EJ, Levine K, Fang Z-H, Jasaityte S, Martinez A-LG, Cullinane P, De Pablo-Fernandez E, Blauwendraat C, Singleton AB, Scholz SW, Traynor BJ, Wood N, Hardy J, Chinnery P, Houlden H, Cain R, Troakes C, Chelban V, Serrano GE, Gveric D, McLean C, Love S, King A, Robinson AC, Roncaroli F, Shepherd C, Halliday G, Parkkinen L, Morris CM, Smith C, Beach TG, Gentleman S, Warner TT, Lashley T, Jaunmuktane Z, Real R, Morris HR, Global Parkinson’s Genetic Program (GP2) . JAMA Neurol, 2026 Aug 1; 83 (8): 798 - 807.Journal ArticlePathology and Genetics in a Global Cohort of Parkinsonian Disorders.
DOI:10.1001/jamaneurol.2026.1634 PMID: PMC13247843 -
Song Y, Rosano C, Chahine LM, Rosso AL, Ambrosio F, Bohnen N, Chen Z, Kim S. Journals of Gerontology Series A Biological Sciences and Medical Sciences, 2026 Jul 1; 81 (7):Journal ArticleA Bayesian network analysis of gait speed change upon transition to uneven surfaces in older adults
DOI:10.1093/gerona/glag137 PMID: 42184285 -
Hart AA, Kanel P, Barr J, Carli G, Vangel R, Michalakis F, Scott PJH, Roytman S, Bohnen NI. European Journal of Neuroscience, 2026 Jul 1; 64 (1):Journal ArticleTopography of Regional Cerebral GABAA Receptor Availability in Parkinson's Disease Patients With Freezing of Gait
DOI:10.1111/ejn.70618 PMID: 42400317 -
Pongmala C, Roytman S, van Emde Boas M, Vangel R, Rosano C, Bohnen N. 2026 Jun 8; medRxiv,PreprintEffect of levodopa treatment on gait in older adults with mild parkinsonian signs
DOI:10.64898/2026.06.04.26354926 -
Bohnen N. 2026 Sep 17;PresentationParkinson's disease
-
Bohnen N. 2026 Sep 17;PresentationWhole brain 11C-PE2I dopamine transporter PET imaging in persons with Parkinson's with freezing of gait or fall
-
Bohnen NI, Roytman S, Carli G, Chou KL, Kanel P, Albin RL. Neural Regen Res, 2026 Jun 8;Journal ArticleCholinergic system changes in levodopa-unresponsive freezing of gait and failure of goal-directed motor behavior in Parkinson's disease.
DOI:10.4103/NRR.NRR-D-25-01957 -
Carli G, Brown T, Michalakis F, Biddix A, Roytman S, Vangel R, Van Hout A, Kanel P, Scott P, Albin RL, Bohnen NI. Brain, 2026 May 12;Journal ArticleWhite matter lesions disrupt cholinergic pathways important for cognition in Parkinson's disease.
DOI:10.1093/brain/awag172 PMID: 42117428